ResearchMoz

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013

GlobalData
Published Date » 2013-11-30
No. Of Pages » 159
 GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Q3 2013 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q3 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and...
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2013 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2013 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
2.4.1 Shoppers Drug Mart Receives Ontario Court Approval for Its Acquisition by Loblaw for US$11.93 Billion 19
2.4.2 Amgen Completes Tender Offer to Acquire Onyx Pharma for up To US$10.4 Billion 21
2.4.3 Community Health Systems to Acquire Health Management Associates for up to US$7.6 Billion 22
2.4.4 Fresenius to Acquire 43 Hospitals from Rhon-Klinikum for US$4.1 Billion 23
2.4.5 Tenet Healthcare Prices Private Placement of Notes Due 2022 for US$2.8 Billion 24

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2013 25
3.1.1 Top M&A Deals in Q3 2013 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2012 - Q3 2013 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2013 29
3.2.1 Top Initial Public Offerings in Q3 2013 31
3.2.2 Top Secondary Offerings in Q3 2013 31
3.2.3 Top PIPE Deals in Q3 2013 31
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2012 - Q3 2013 33
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2013 35
3.3.1 Top Venture Financing Deals in Q3 2013 36
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 37
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 38
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2012 - Q3 2013 39
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 41
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2013 44
3.4.1 Top Private Equity Deals in Q3 2013 45
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2012 - Q3 2013 46

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2012 - Q3 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 61

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2012 - Q3 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 76

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2012 - Q3 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2012 - Q3 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2012 - Q3 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2012 - Q3 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2013 92
7.1.1 Oncology - Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2013 96
7.2.1 Central Nervous System - Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2013 101
7.3.1 Infectious Disease - Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2013 105
7.4.1 Immunology - Deals of the Quarter 107
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2013 108
7.5.1 Metabolic Disorders - Deals of the Quarter 110
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2013 112
7.6.1 Cardiovascular - Deals of the Quarter 114
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2013 116
7.7.1 Gastrointestinal - Deals of the Quarter 118
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2013 119
7.8.1 Dermatology - Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2013 122
7.9.1 Respiratory - Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2013 126
7.10.1 Ophthalmology - Deals of the Quarter 128

8 Deal Summary by Geography 130
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2013 130
8.1.1 North America - Deals of the Quarter 132
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2013 135
8.2.1 Europe - Deals of the Quarter 137
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2013 139
8.3.1 Asia-Pacific - Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2013 144
8.4.1 Rest of the World - Deals of the Quarter 146

9 Pharmaceuticals & Healthcare, Global, Top Advisors 148
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 148
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 150

10 Appendix 152

11 Further Information 156
11.1 Methodology 156
11.2 About GlobalData 157
11.3 Disclosure information 158
11.4 Disclaimer 158

List of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 16
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2013 19
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 26
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2013 26
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2012 - Q3 2013 28
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 30
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2013 31
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2013 31
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2013 31
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 34
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 36
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2013 36
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number of Deals and Deal Values (%), Q3 2013 38
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 40
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 42
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 45
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2013 45
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 47
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 49
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 51
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 53
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 54
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2013 55
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 57
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 60
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 62
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 64
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 66
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2013 67
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2013 67
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2013 68
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 70
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2012 - Q3 2013 72
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 75
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 77
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 79
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 81
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 83
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2012 - Q3 2013 85
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 87
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 89
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 91
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 93
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 97
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 102
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 106
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 109
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 113
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 117
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 120
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 123
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 127
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 131
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 136
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 140
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 145
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 149
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 151
Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q3 2012-Q3 2013 152

List of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2013 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2013 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 25
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2012 - Q3 2013 27
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 29
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2012 - Q3 2013 33
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 35
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2013 37
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2013 38
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 39
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 41
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 44
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 46
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 48
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 50
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 52
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 56
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 58
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 59
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 61
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 63
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 69
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 71
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 73
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 74
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 76
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 78
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 80
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 86
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 88
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 92
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 96
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 101
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 105
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 108
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 112
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 116
Figure 43: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 119
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 122
Figure 45: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 126
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 130
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 135
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 139
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 144
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 148
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 150

Upcoming Reports:

Poland: mineral and aerated water market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the mineral and aerated water market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the mineral and aerated water market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
Hysterectomy Alternatives Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Hysterectomy is the process where complete or partial uterus is removed from the women’s body by the gynecologist. In complete uterus removal, fundus, cervix and body of the uterus are removed whereas in partial only body of the uterus is excised.Hysterectomy is performed when a women is suffering from fibroids, uterine prolapse, endometriosis, chronic pelvic pain, vaginal bleeding and cancer of uterus, ovaries and cervix. It has been observed in U.S. that 1 out of 3 women are undergoing hysterectomy annually. Hysterectomy has various issues such as hormonal imbalance,...
GPON Equipment Market - Global Industry size, market share, trends, analysis and forecasts 2012 - 2018
By - Transparency Market Research
Passive optical network (PON) is a network architecture that brings fiber cabling and signals to home using point to multipoint scheme that enables single optical fiber to serve multiple premises. This architecture makes use of passive optical splitters that helps in reducing cost of equipments compared to point to point architecture.  Gigabit passive optical network (GPON) standard differs from other PON standards as it offers better bandwidth and higher efficiency using larger, variable length packets. GPON equipment market is expected to witness significant growth in...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Demand for Big-Screen iPhones Observed More by 4 Million than for Earlier Versions
Sep 16, 2014  
Apple Inc. has observed pre-orders more than 4 million for its new version of iPhone as compared to what was observed for previous versions of iPhones, in the first 24 hours of launch. The demand for the smartphones already seems to outstrip supply, expected to start by the end of this week.   iPhone 6 and iPhone 6 Plus, company’s recent smartphone launches with bigger...
LiquidM Launches New Mobile with Improved Retargeting Facilities
Sep 15, 2014  
Mobile Advertising Management Platform (MAMP) the only white-labeled LiquidM introduced retargeting capabilities in its newly launched mobile today. These capabilities help the mobile advertisers and developers reestablish contacts with their customers. It helps remind people to revisit the website, complete the purchase or remind people who have already visited the website for digital...
Open to Hiring Malaysia Airlines Retrenched Employees : AirAsia CEO
Sep 11, 2014  
After reports that Malaysia Airlines will be letting go nearly 6,000 of its staff, chief executive officer of low-cost carrier AirAsia Tan Sri Tony Fernandes has said that he is open to hiring MAS ex-employees as part of its own workforce.  Fernandes said that he welcomes the MAS overhaul and the transition will be a good move for the AirAsia group as well as Malaysia Airlines....
Statoil Expands Natural Gas in Bakken
Sep 11, 2014  
A Norway-based oil company, Statoil known for dealing in natural gas has stamped its strong presence in Bakken, North Dakota. In the last three years, emissions from burning, flaring of methane, natural gas, and hydrogen sulphide related with oil production have risen tremendously. Statoil operates in the effort to expand the technology to power equipment with natural gas that would otherwise...
Apple Watch - The Latest Product Launched By Apple Inc
Sep 11, 2014  
The sale of large screen phones may witness a boost due to the additional feature of mobile payment service that has been included in Apple Inc’s latest iPhone. This could restore the market share of Apple Inc that was lost to Google Inc’s Android segment. Soon after the launch of the Apple Watch and iPhone 6, the shares of Apple rose by almost 1.3% on Wednesday. This also...